Strong Promoters Are the Key to Highly Efficient, Noninflammatory and Noncytotoxic Adenoviral-Mediated Transgene Delivery into the Brain in Vivo
Open Access
- 31 October 2000
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 2 (4), 330-338
- https://doi.org/10.1006/mthe.2000.0140
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Transcriptional Targeting to Anterior Pituitary Lactotrophic Cells Using Recombinant Adenovirus Vectors in Vitro and in Vivo in Normal and Estrogen/Sulpiride-Induced Hyperplasic Anterior Pituitaries*Endocrinology, 2000
- Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trialsNature Medicine, 1999
- Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity.Journal of General Virology, 1999
- A triploblast origin for Myxozoa?Nature, 1998
- Adenovirus-mediated expression of an elastase-specific inhibitor (elafin): a comparison of different promotersGene Therapy, 1998
- Sensitivity and reproducibility in adenoviral infectious titer determinationNature Medicine, 1997
- Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors.Journal of General Virology, 1997
- Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors.Journal of General Virology, 1997
- Immune responses to adenovirus vectors in the nervous systemTrends in Neurosciences, 1996
- Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vectorNucleic Acids Research, 1992